NCT04844359

A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis

Development and Validation of a Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 137 (actual)
• Sponsor: National Jewish Health · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Up to 150 patients with hypersensitivity pneumonitis will be enrolled at 7 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood can predict disease progression.

Detailed description

Hypersensitivity pneumonitis is an immunologically mediated form of lung disease, resulting from inhalation exposure to a large variety of antigens. For unknown reasons, a subgroup of patients with HP without a known inciting antigen exposure develops chronic disease with progressive pulmonary fibrosis (the leading cause of death). Accurately identifying patients at risk of disease progression is necessary for prognosis and therapy. Enrolled subjects will be followed for 24 months and complete 5 visits to one of the study centers. Blood biomarkers will be collected in addition to other clinical data to determine if these biomarkers can predict disease progression.

Conditions

• Hypersensitivity Pneumonitis

Timeline

• Start date: 2021-01-06
• Primary completion: 2026-07-30
• Completion: 2026-07-31
• First posted: 2021-04-14
• Last updated: 2026-04-09

Locations

7 sites across 1 country: United States